Kate’s work on the Technology Development team focuses on developing base editing therapeutics.

Prior to joining Life Edit, Kate worked at Locus Biosciences where she engineered phage with Type I CRISPR systems as a novel antibacterial therapeutic.

Kate completed a postdoctoral fellowship at Beth Israel Deaconess Medical Center/Harvard Medical school where she identified small molecule inhibitors of plasmid maintenance in drug resistant bacterial strains. She received her PhD in Microbiology and Immunology at the University of North at Chapel Hill where she studied protein secretion and host-pathogen interactions of Mycobacterium tuberculosis.